Radiofrequency ablation using a switching controller for lung neopasms

Radiofrequency ablation using a switching controller for lung neopasms - RFA using a switching controller for lung neopasms

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002504

Enrollment

Registered

2009-09-16

Start date

2009-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malignant lung neoplasms

Interventions

12-month enrollment, 12-month follow-up. Number of subjects: 33.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients with malignant lung neoplasms diagnosed by biopsy or radiographic findings (CT or PET-C). 2. The maximum tumor size of 2-5cm with a tumor number of 3 or less. 3. SpO2 of 92% or more. 4. Not a surgical candidate. 5. No abnormality in major organs. a) white blood count of 3000/mm3 or more. b) Hgb of 8.0g/dl. c) Cr of 2.0mg/dl or less. d) bil of 2.0mg/dl or less. 6. Age of 20 years or more. 7. PS of 0 or 1. 8. Life expectancy of 2 months or more. 9. Informed consent from the patient.

Exclusion criteria

Exclusion criteria: 1. Abnormal coagulability. a) platelet count of 50000 or less. b) INR of less than 1.5. 2. Previous radiotherapy.

Design outcomes

Primary

Measure	Time frame
Complication after lung radiofrequency.	—

Countries

Japan

Contacts

Public ContactKoichiro Yamakado

Mie University Hospital Interventional Radiology

yama@clin.medic.mie-u.ac.jp059-231-5029

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026